drugset / Trial / NCT02049164
Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.
Timeline
- Start
- 2014-01
- Primary completion
- 2014-05
- Completion
- 2014-05
Outcome
Outcome not reported
Stopped: “Study stopping criteria met with regards to vital sign measurements post dose.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AR08 | Unknown | 0.5 mg | Oral |
| Subject | AR08 | Unknown | 1 mg | Oral |
| Subject | AR08 | Unknown | 2 mg | Oral |
Indications
No indication recorded.